🟢 Xencor is trading 4.3% up with no identified company-specific catalyst

Xencor is trading 4.32% up now at $30.94 on November 3, 2026, with no new company-specific announcement identified to explain the rise.

• The latest major catalyst was the October 25 XmAb819 kidney-cancer trial update, which had already driven a sharp rally.
• Biotech ETF XBI is up 2.13% in the regular session amid sector rotation, but this does not establish the cause.
• Xencor is due to report Q3 results on November 4; earnings approaching alone does not explain the move.